Datopotamab Deruxtecan, often abbreviated as DATO, represents the important advancement in targeted cancer therapy. This novel antibody-drug conjugate pairs the monoclonal antigen specifically targeting HER-2 expressing cells with an potent cytotoxic payload, deruxtecan. The mechanism of action involves the antibody's power to attach to malignant c